Fortress Biotech Inc. (NASDAQ:FBIO) and CytomX Therapeutics Inc. (NASDAQ:CTMX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech Inc.	228.27M	0.51	69.68M	-0.66	0.00
CytomX Therapeutics Inc.	59.50M	8.31	84.60M	-1.93	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Fortress Biotech Inc. and CytomX Therapeutics Inc.

Profitability

Table 2 shows us Fortress Biotech Inc. and CytomX Therapeutics Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Fortress Biotech Inc.	-30.53%	-158.4%	-28.7%
CytomX Therapeutics Inc.	-142.18%	-65%	-12.7%

Liquidity

Fortress Biotech Inc. has a Current Ratio of 2.3 and a Quick Ratio of 2.2. Competitively, CytomX Therapeutics Inc.’s Current Ratio is 5.5 and has 5.5 Quick Ratio. CytomX Therapeutics Inc.’s better ability to pay short and long-term obligations than Fortress Biotech Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Fortress Biotech Inc. and CytomX Therapeutics Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Fortress Biotech Inc.	0	0	1	3.00
CytomX Therapeutics Inc.	0	0	1	3.00

Fortress Biotech Inc.’s average price target is $11, while its potential upside is 439.22%. Competitively the average price target of CytomX Therapeutics Inc. is $25, which is potential 127.69% upside. The information presented earlier suggests that Fortress Biotech Inc. looks more robust than CytomX Therapeutics Inc. as far as analyst opinion.

Institutional and Insider Ownership

Institutional investors held 15.4% of Fortress Biotech Inc. shares and 86.6% of CytomX Therapeutics Inc. shares. Fortress Biotech Inc.’s share held by insiders are 0.4%. Insiders Comparatively, held 0.2% of CytomX Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Fortress Biotech Inc.	-11.48%	-0.92%	-32.5%	-67.37%	-69.75%	-72.93%
CytomX Therapeutics Inc.	4.49%	-9.59%	-28.08%	-39.64%	-28.33%	-31.69%

For the past year CytomX Therapeutics Inc. has weaker performance than Fortress Biotech Inc.

Summary

Fortress Biotech Inc. beats on 6 of the 11 factors CytomX Therapeutics Inc.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders. In addition, the company is developing novel immunotherapies for the prevention and treatment of cancer and infectious disease; Targadox for severe acne; Luxamend, a wound cream; Ceracade, a skin emulsion; Chimeric Antigen Receptor that is in Phase I clinical trial for acute myeloid leukemia and brain cancer; and MB-101, which is in Phase I clinical trial for glioblastoma. Further, it offers full service retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities, such as making markets in micro and small-cap NASDAQ, and other exchange listed stocks; liquidity services in the United States Treasury marketplace; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. Its other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188. In addition, the company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., M D Anderson Cancer Center, Pfizer Inc., and The University of Texas to develop Probody therapeutics. It also has a strategic collaboration with Amgen Inc. to co-develop a CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor, a validated oncology target expressed on multiple human cancer types. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.